Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Sonnet Biotherapeutics stock (SONN)

Buy Sonnet Biotherapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Sonnet Biotherapeutics is a biotechnology business based in the US. Sonnet Biotherapeutics shares (SONN) are listed on the NASDAQ and all prices are listed in US Dollars. Sonnet Biotherapeutics employs 12 staff and has a trailing 12-month revenue of around $92,731.

Our top picks for where to buy Sonnet Biotherapeutics stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Sonnet Biotherapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – SONN. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Sonnet Biotherapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 5 of 5
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Moomoo
Finder Score: 4.3 / 5: ★★★★★
Exclusive
Moomoo
★★★★★
Stocks, Options, ETFs
$0
$0
Up to 8.10%
Get up to 15 free stocks
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Public.com
Finder Score: 4.2 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
5.1%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Sonnet Biotherapeutics stock price (NASDAQ: SONN)

Use our graph to track the performance of SONN stocks over time.

Sonnet Biotherapeutics shares at a glance

Information last updated 2024-07-21.
Latest market close$0.85
52-week range$0.83 - $10.09
50-day moving average $1.35
200-day moving average $1.58
Wall St. target price$27.00
PE ratio 0.3025
Dividend yield N/A (0%)
Earnings per share (TTM) $2.81

Is it a good time to buy Sonnet Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sonnet Biotherapeutics price performance over time

Historical closes compared with the close of $0.852 from 2024-07-23

1 week (2024-07-17) -5.33%
1 month (2024-06-24) -6.99%
3 months (2024-04-24) -53.82%
6 months (2024-01-24) -38.62%
1 year (2023-07-24) 130.27%
2 years (2022-07-22) 193.79%
3 years (2021-07-23) 1.04
5 years (2019-07-24) 20.2826

Is Sonnet Biotherapeutics stock undervalued or overvalued?

Valuing Sonnet Biotherapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sonnet Biotherapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sonnet Biotherapeutics's P/E ratio

Sonnet Biotherapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Sonnet Biotherapeutics shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Sonnet Biotherapeutics financials

Revenue TTM $92,731
Gross profit TTM $-21,094,076
Return on assets TTM -82.35%
Return on equity TTM -200.09%
Profit margin 0%
Book value $0.98
Market Capitalization $4.4 million

TTM: trailing 12 months

Sonnet Biotherapeutics share dividends

We're not expecting Sonnet Biotherapeutics to pay a dividend over the next 12 months.

Have Sonnet Biotherapeutics's shares ever split?

Sonnet Biotherapeutics's shares were split on a 1:22 basis on 31 August 2023. So if you had owned 22 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sonnet Biotherapeutics shares – just the quantity. However, indirectly, the new 2100% higher share price could have impacted the market appetite for Sonnet Biotherapeutics shares which in turn could have impacted Sonnet Biotherapeutics's share price.

Sonnet Biotherapeutics share price volatility

Over the last 12 months, Sonnet Biotherapeutics's shares have ranged in value from as little as $0.825 up to $10.087. A popular way to gauge a stock's volatility is its "beta".

SONN.US volatility(beta: 0.99)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sonnet Biotherapeutics's is 0.989. This would suggest that Sonnet Biotherapeutics's shares are less volatile than average (for this exchange).

Sonnet Biotherapeutics overview

Sonnet BioTherapeutics Holdings, Inc. , a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6.

Frequently asked questions

What percentage of Sonnet Biotherapeutics is owned by insiders or institutions?
Currently 5.423% of Sonnet Biotherapeutics shares are held by insiders and 1.549% by institutions.
How many people work for Sonnet Biotherapeutics?
Latest data suggests 12 work at Sonnet Biotherapeutics.
When does the fiscal year end for Sonnet Biotherapeutics?
Sonnet Biotherapeutics's fiscal year ends in December.
Where is Sonnet Biotherapeutics based?
Sonnet Biotherapeutics's address is: 100 Overlook Center, Princeton, NJ, United States, 08540
What is Sonnet Biotherapeutics's ISIN number?
Sonnet Biotherapeutics's international securities identification number is: US83548R1059
What is Sonnet Biotherapeutics's CUSIP number?
Sonnet Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 15930P503

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site